Jejunoileal bypass reversal: effect on renal function, metabolic parameters and stone formation.
OBJECTIVE
While the effect of jejunoileal bypass (JIB) reversal has been well studied regarding hepatic function, there is little information regarding the effect of reversal on renal function and even less data regarding the metabolic urinary stone environment. We evaluated the results of JIB reversal on renal function, the urinary stone milieu and the clinical development of recurrent calculi in affected patients.


METHODS
From 1995 to 2003, 4 female patients with a mean age of 48.2 years underwent JIB reversal primarily for refractory stone disease. The clinical and metabolic courses prior to and following bypass reversal were reviewed specifically to evaluate renal function, serum and urinary metabolic stone profiles, and clinical stone formation.


RESULTS
At initial presentation following JIB all 4 patients had significantly increased 24-hour urinary oxalate (range 80 to 160 mg, mean 112.5, normal less than 50) and significantly low 24-hour urinary citrate (range 5 to 62 mg, mean 21.5, normal greater than 320). Following reversal 24-hour urinary oxalate normalized to between 31 and 36 mg (mean 33.75). However, 24-hour urinary citrate continued to be low (range 215 to 248 mg, mean 226.5). After JIB reversal all 4 patients continued to have new stones until the commencement of urinary alkalization, following which only 1 had 1 calculus, which occurred 47 months after reversal. After JIB mean serum creatinine was 1.48 mg/dl (range 0.8 to 1.9) and mean urinary creatinine excretion was 0.91 mg per hour (range 0.69 to 1.15). After JIB reversal mean serum creatinine was 1.28 mg/dl (range 0.6 to 2.0) and mean urinary creatinine excretion was 1.0 mg per hour (range 0.85 to 1.10).


CONCLUSIONS
JIB reversal normalizes 24-hour urinary oxalate. While urinary citrate improves, it continues to be low and such patients are at high risk for recurrent stone formation. However, in this setting appropriate replacement therapy has a significant and positive impact on that propensity.
Dhar
Nivedita Bhatta
NB
Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. dharn@ccf.org
Grundfest
Sharon
S
Jones
Jace S
JS
Streem
Stevan B
SB
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007408:Intestinal Absorption; D007581:Jejunoileal Bypass / Q000379:methods*; D007669:Kidney Calculi / Q000737:chemistry* / Q000175:diagnosis / Q000601:surgery*; D007677:Kidney Function Tests; D010070:Oxalates / Q000378:metabolism* / Q000652:urine; D011336:Probability; D012086:Reoperation; D018570:Risk Assessment; D012494:Sampling Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014545:Urinary Calculi / Q000737:chemistry / Q000175:diagnosis / Q000601:surgery
D010070:Oxalates